Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Baxter
Merck
Dow
Moodys

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Rimabotulinumtoxinb - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Summary for rimabotulinumtoxinb
Tradenames:1
Patents:4
Applicants:1
BLAs:1
Suppliers: see list1
Pharmacology for rimabotulinumtoxinb
Mechanism of ActionAcetylcholine Release Inhibitors
Established Pharmacologic ClassAcetylcholine Release Inhibitor
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rimabotulinumtoxinb Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rimabotulinumtoxinb Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Solstice Neurosciences, Llc MYOBLOC rimabotulinumtoxinb Injection 103846 ⤷  Sign up for a Free Trial 2013-12-28 Company disclosures
Solstice Neurosciences, Llc MYOBLOC rimabotulinumtoxinb Injection 103846 ⤷  Sign up for a Free Trial 2013-12-28 Company disclosures
Solstice Neurosciences, Llc MYOBLOC rimabotulinumtoxinb Injection 103846 ⤷  Sign up for a Free Trial 2013-06-10 Company disclosures
Solstice Neurosciences, Llc MYOBLOC rimabotulinumtoxinb Injection 103846 ⤷  Sign up for a Free Trial 2013-12-28 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for rimabotulinumtoxinb Derived from Patent Text Search

These patents were obtained by searching patent claims

International Patents for rimabotulinumtoxinb

Country Patent Number Estimated Expiration
Spain 2340172 ⤷  Sign up for a Free Trial
Japan 2002097145 ⤷  Sign up for a Free Trial
Japan 2010202659 ⤷  Sign up for a Free Trial
Australia 7087894 ⤷  Sign up for a Free Trial
Germany 69435149 ⤷  Sign up for a Free Trial
European Patent Office 1757325 ⤷  Sign up for a Free Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for rimabotulinumtoxinb

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
132010901814274 Italy ⤷  Sign up for a Free Trial AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/166/001-003, 20010122
132008901655480 Italy ⤷  Sign up for a Free Trial PRODUCT NAME: NEUROTOSSINA DI CLOSTRIDIUM BOTULINUM DI TIPO A (150 KD) PRIVA DI PROTEINE COMPLESSATE(XEOMIN); AUTHORISATION NUMBER(S) AND DATE(S): 838, 20080409;57093.00.00, 20050531
122008000042 Germany ⤷  Sign up for a Free Trial PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
10C0007 France ⤷  Sign up for a Free Trial PRODUCT NAME: TOXINE BOTULIQUE DE TYPE B; REGISTRATION NO/DATE: EU/1/00/166/001 20010122
122008000043 Germany ⤷  Sign up for a Free Trial PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
122009000066 Germany ⤷  Sign up for a Free Trial PRODUCT NAME: BOTULINUMTOXIN TYP B; REGISTRATION NO/DATE: EU/1/00/166/001-003 20010122
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Johnson and Johnson
Mallinckrodt
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.